Editorial Open Access
Like 0
Preview this article:
Zoom in

No country or continent is on its own in the ongoing COVID-19 pandemic, Page 1 of 1

| /docserver/preview/fulltext/eurosurveillance/26/17/eurosurv-26-17-1-1.gif

There is no abstract available for this article.
Use the preview function to the left.


Article metrics loading...

Loading full text...

Full text loading...



  1. Cohen J. Chinese researchers reveal draft genome of virus implicated in Wuhan pneumonia outbreak. AAAS; 2020. Available from: https://www.sciencemag.org/news/2020/01/chinese-researchers-reveal-draft-genome-virus-implicated-wuhan-pneumonia-outbreak
  2. World Health Organization (WHO). WHO candidate tracker COVID-19 – Landscape of novel coronavirus candidate vaccine development worldwide. Geneva: WHO; 2021. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
  3. European Medicines Agency (EMA). EMA Guidance for medicine developers and other stakeholders on COVID-19. Amsterdam: EMA; 2020. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/guidance-medicine-developers-other-stakeholders-covid-19
  4. European Medicines Agency (EMA). EMA COVID-19: latest updates. Amsterdam: EMA; 2020. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-latest-updates
  5. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;S0140-6736(21)00677-2.  https://doi.org/10.1016/S0140-6736(21)00677-2 
  6. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA 1273 COVID-19 Vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers – eight US locations, December 2020 – March 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500.  https://doi.org/10.15585/mmwr.mm7013e3  PMID: 33793460 
  7. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. , ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;  https://doi.org/10.1056/NEJMoa2101544  PMID: 33882225 
  8. European Centre for Disease Prevention and Control (ECDC). ECDC COVID-19 Vaccine tracker. Stockholm: ECDC. [Accessed: 28 Apr 2021]. Available from: https://qap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab
  9. COVAX. A global risk-sharing mechanism from pooled procurement and equitable distribution of COVID-19 vaccines. Geneva: Gavi. [Accessed: 28 Apr 2021]. Available from: https://www.gavi.org/covax-facility
  10. World Health Organization (WHO). WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. Geneva: WHO; 2020. Available from: https://www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination
  11. World Health Organization (WHO). WHO SAGE Roadmap For Prioritizing Uses Of COVID-19 Vaccines In The Context Of Limited Supply. Geneva: WHO; 13 Nov 2020. Available from: https://www.who.int/publications/m/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines-in-the-context-of-limited-supply-
  12. European Centre for Disease Prevention and Control (ECDC). EU/EEA NITAG Collaboration. Stockholm: ECDC. [Accessed: 28 Apr 2021]. Available from: https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/national-immunisation-technical-advisory-groups-nitag
  13. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;NEJMoa2104882.  https://doi.org/10.1056/NEJMoa2104882  PMID: 33835768 
  14. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021;  https://doi.org/10.1056/NEJMoa2104840  PMID: 33835769 
  15. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021;NEJMoa2105385.  https://doi.org/10.1056/NEJMoa2105385  PMID: 33861525 
  16. European Medicines Agency (EMA). Vaxzevria. Summary of product characteristics. Amsterdam: EMA. [Accessed: 28 Apr 2021]. Available from: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf
  17. Our world in data. England: Global Change Data Lab. [Accessed: 28 Apr 2021]. Available from: https://ourworldindata.org/
  18. World Health Organization (WHO). WHO R&D Blueprint COVID-19 new variants: Knowledge gaps and research. Geneva: WHO; 12 Jan 2021. Available from: https://cdn.who.int/media/docs/default-source/blue-print/covid-19-new-variants-meeting-report_20.03.2012.pdf?sfvrsn=5ac5785_3&download=true
  19. World Health Organization (WHO). Statement on the seventh meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic. Geneva: WHO; 19 Apr 2021. Available from: https://www.who.int/news/item/19-04-2021-statement-on-the-seventh-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
  20. World Health Organization (WHO). WHO Weekly Epi Update from 13 April. Geneva: WHO; 2021. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-april-2021
  21. United States Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants. Washington: 22 Feb 2021. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-addressing-virus
  22. European Medicines Agency (EMA). Regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2. Amsterdam: EMA; 25 Feb 2021. Available from: https://www.ema.europa.eu/en/regulatory-requirements-vaccines-intended-provide-protection-against-variant-strains-sars-cov-2
  23. European Medicines Agency (EMA). EMA and ECDC join forces for enhanced post-marketing monitoring of COVID-19 vaccines in Europe. Amsterdam: EMA; 26 Apr 2021. Available from: https://www.ema.europa.eu/en/news/ema-ecdc-join-forces-enhanced-post-marketing-monitoring-covid-19-vaccines-europe
  24. Moyo-Gwete T, Madzivhandila M, Makhado Z. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies; bioRxiv; 2021. Available from: https://www.biorxiv.org/content/10.1101/2021.03.06.434193v1
  25. Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al.; Network for Genomic Surveillance in South Africa. COMMIT-KZN Team. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021.  https://doi.org/10.1038/s41586-021-03471-w  PMID: 33780970 
  26. European Centre for Disease Prevention and Control (ECDC). ECDC Interim guidance on the benefits of full vaccination against COVID-19 for transmission and implications for non-pharmaceutical interventions. Stockholm: ECDC; 21 Apr 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Interim-guidance-benefits-of-full-vaccination-against-COVID-19-for-transmission-and-implications-for-non-pharmaceutical-interventions.pdf
  27. Rohleder S, Stock C, Bozorgmehr K. Socioeconomic deprivation is inversely associated with measles incidence: a longitudinal small-area analysis, Germany, 2001 to 2017. Euro Surveill. 2021;26(17):1900755.  https://doi.org/10.2807/1560-7917.ES.2021.26.17.1900755 
  28. Williams SR, Driscoll AJ, LeBuhn HM, Chen WH, Neuzil KM, Ortiz JR. National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines. Euro Surveill. 2021;26(17):2001195.  https://doi.org/10.2807/1560-7917.ES.2021.26.17.2001195 
  29. von Linstow ML, Yde NA, Kirkby N, Eltvedt A, Nordmann WT, Bybeck NA, et al. Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019. Euro Surveill. 2021;26(17):2001167.  https://doi.org/10.2807/1560-7917.ES.2021.26.17.2001167 
  30. European Centre for Disease Prevention and Control (ECDC). Objectives of vaccination strategies against COVID-19. Stockholm: ECDC; 23 Apr 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/objectives-vaccination-strategies-against-covid-19
  31. Robert Koch Institut (RKI). Standard Operating Procedure of the German Standing Committee on Vaccinations (STIKO) for the systematic development of vaccination recommendations, Version 3.1. Berlin: RKI; 14 Nov 2018. Available from: https://www.rki.de/EN/Content/infections/Vaccination/methodology/SOP.pdf?__blob=publicationFile

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error